Overview

* Venus Concept Q3 2025 revenue down 8% yr/yr, missing analyst expectations

* Net loss widened to $22.5 mln in Q3, compared to $9.3 mln last year

* Company completed debt-to-equity exchange, reducing debt by 24%

Outlook

* Company is not providing financial guidance for fiscal year 2025

* Company targets sequential growth in Q4 with Venus NOVA launch

* Company faces challenges in closing Venus Hair Business sale

Result Drivers

* EBD STABILIZATION - Venus Concept ( VERO ) reports signs of stabilization in energy-based device revenues

* HAIR BUSINESS DELAY - Decline in Venus Hair Business revenue due to delay in pending sale

* VENUS NOVA LAUNCH - FDA clearance received for Venus NOVA, expected to drive future growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $13.8 $14.48

Revenue mln mln (1

Analyst)

Q3 EPS -$12.14

Q3 Net -$22.50

Income mln

Q3 -$7.80

Adjusted mln

EBITDA

Q3 Gross 64.00%

Margin

Q3 -$9.50

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)